1GH Stock Overview

A precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. More details

1GH fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 84.1% below our estimate of its fair value

Revenue is forecast to grow 17.23% per year

Analysts in good agreement that stock price will rise by 49%

Risk Analysis

Shares are highly illiquid

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Guardant Health, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Guardant Health
Historical stock prices
Current Share Price	US$35.18
52 Week High	US$36.84
52 Week Low	US$36.84
Beta	1.49
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-14.78%

Recent updates

Shareholder Returns

	1GH	IT Healthcare	IT Market
7D	-4.5%	-2.5%	1.1%
1Y	n/a	19.6%	16.1%

Return vs Industry: Insufficient data to determine how 1GH performed against the Italian Healthcare industry.

Return vs Market: Insufficient data to determine how 1GH performed against the Italian Market.

Price Volatility

Is 1GH's price volatile compared to industry and market?
1GH volatility
1GH Average Weekly Movement	n/a
Healthcare Industry Average Movement	5.6%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1GH's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1GH's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	2,010	Helmy Eltoukhy	guardanthealth.com

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform.

Guardant Health, Inc. Fundamentals Summary

How do Guardant Health's earnings and revenue compare to its market cap?
1GH fundamental statistics
Market cap	€4.42b
Earnings (TTM)	-€369.27m
Revenue (TTM)	€686.15m

6.4x

P/S Ratio

-11.9x

P/E Ratio

Is 1GH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1GH income statement (TTM)
Revenue	US$774.00m
Cost of Revenue	US$299.23m
Gross Profit	US$474.77m
Other Expenses	US$891.32m
Earnings	-US$416.55m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-3.36
Gross Margin	61.34%
Net Profit Margin	-53.82%
Debt/Equity Ratio	-445.1%

How did 1GH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/20 06:10
End of Day Share Price	2025/05/20 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guardant Health, Inc. is covered by 30 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Luke Sergott	Barclays
Michael Ryskin	BofA Global Research
Mark Massaro	BTIG

Guardant Health BIT:1GH Stock Report